PACIFIC EDGE LIMITED — Capital/Financing Update 2019

Nov 21, 2019

==> picture [235 x 58] intentionally omitted <==

PACIFIC EDGE – COMPLETION OF PLACEMENT

22 November 2019

Pacific Edge Limited (Pacific Edge) is pleased to announce the successful completion of its $7m underwritten placement announced on 21 November 2019, with strong support from new and existing investors, both in New Zealand and internationally. Approximately 46.7 million shares will be issued at the offer price of $0.15 per share. Settlement and allotment of the new shares will occur on 26 November 2019.

Pacific Edge Chairman Chris Gallaher said “We are pleased with the support we have received from investors for the first phase of our capital raising, reflecting their confidence in our strategy and our future prospects. We are delighted to welcome a number of new local and international investors to our register, alongside strong support from our existing shareholders.”

The fully underwritten, pro rata renounceable 1 for 4.25 Rights Offer component of the capital raising, at $0.10 per share, will open for rights trading on 28 November 2019. Eligible shareholders holding shares at 5.00pm on the record date of 29 November 2019 will be able to participate in the Rights Offer.

The Offer Document and the Entitlement and Acceptance Form will be released on NZX on 28 November 2019. Eligible shareholders will be able to participate by applying at http://pacificedgeshareoffer.co.nz or returning their Entitlement and Acceptance Form to the registrar with payment for their new shares.

Pacific Edge shares will recommence trading upon market opening today.

- ENDS –

For more information contact:

David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies. Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

==> picture [235 x 58] intentionally omitted <==

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires lifelong surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.